



Supplementary Figure 1. Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline: intention-to-treat set analysis. Mixed-model repeated-measures analysis results showing the change in PANSS total score for lurasidone 160 mg/day and quetiapine XR 600 mg/day (intention-to-treat set). Results are shown as weekly least squares mean (LS mean)±standard error during 6 weeks of the double-blind trial period. *p<0.05 vs. quetiapine XR. W 1–6, week 1–6.